Impact Factor 4.716 | CiteScore 4.71
More on impact ›

Correction ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.02515

Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy

  • 1Université Toulouse III Paul Sabatier, France
  • 2INSERM U1037 Centre de Recherche en Cancérologie de Toulouse, France

In the original article, there was an error. We stated that Infliximab is a « a first-generation humanized TNF blocking antibody ». Actually, Infliximab is « a first-generation chimeric TNF blocking antibody ».
A correction has been made to the section “Combining TNF Blockade to Immune Checkpoint Blockers to Treat Melanoma”, first Paragraph:
Interestingly, Infliximab, a first-generation chimeric TNF blocking antibody is currently being used in the clinic to treat some of the irAEs, mainly colitis, sometimes triggered by ICI (31).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: Tumor necrosis factor, Anti-TNF, Melanoma, PD-1, CTLA-4

Received: 07 Oct 2019; Accepted: 08 Oct 2019.

Copyright: © 2019 Ségui, Montfort, Colacios, Levade, ABADIE and Meyer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Bruno Ségui, Université Toulouse III Paul Sabatier, Toulouse, France, bruno.segui@inserm.fr